Cerevel Therapeutics (CERE)
(Delayed Data from NSDQ)
$42.55 USD
-0.04 (-0.09%)
Updated May 3, 2024 04:00 PM ET
After-Market: $42.54 -0.01 (-0.02%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth A Momentum D VGM
Industry / Sector Report
Industry : Medical - Drugs
Zacks Industry Rank
Top 39% (98 out of 252)Zacks Sector Rank
Top 25% (4 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 2.64 | 1.52 | 9.99 |
Current Quarter Estimate | -0.61 | -2.04 | 57.00 |
Year Ago Quarter Estimate | -0.67 | -0.59 | 52.54 |
Next Quarter Estimate | -0.62 | -2.00 | 61.00 |
Next Year Estimate | -2.93 | 6.92 | 270.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | NA | 11.70 | 15.67 |
Next Year | -7.72 | 13.60 | 9.31 |
Last 5 Years | NA | 5.50 | 8.10 |
Next 5 Years | 1.60 | 22.00 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -5.88 |
Price/Book (MRQ) | 11.46 | 1.75 |
Price/Cash Flow (MRFY) | NA | 8.73 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | NA | 0.44% |
Return on Equity (TTM) | -100.14% | -9.69% |
Debt to Equity (MRQ) | NA | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.